Table 2. Real-world studies and their... | American Society of Hematology

Table 2.

Real-world studies and their HGBL data

	No. of centers	Product	Patient characteristics		Clinical outcomes
			Patient characteristics		Total cohort				HGBL
			No. of patients	No. of HGBL	ORR	CR	PFS	OS	ORR	CR	PFS	OS
Nastoupil et al⁵⁶	17	Axicabtagene ciloleucel	275	64	82	63	48	68	NR	64	39	69
Jacobson et al⁵⁷	7	Axicabtagene ciloleucel	122	47	70	—	—	—	86	—	—	—
Iacoboni et al⁵⁸	10	Tisagenlecleucel	75	11	60	—	—	—	63.6	—	—	—

	No. of centers	Product	Patient characteristics		Clinical outcomes
			Patient characteristics		Total cohort				HGBL
			No. of patients	No. of HGBL	ORR	CR	PFS	OS	ORR	CR	PFS	OS
Nastoupil et al⁵⁶	17	Axicabtagene ciloleucel	275	64	82	63	48	68	NR	64	39	69
Jacobson et al⁵⁷	7	Axicabtagene ciloleucel	122	47	70	—	—	—	86	—	—	—
Iacoboni et al⁵⁸	10	Tisagenlecleucel	75	11	60	—	—	—	63.6	—	—	—